Introduction
============

Carbapenems are well-known β-lactam antibiotics with broad spectrum activity that have long been used for treating severe infections caused by otherwise resistant Gram-negative bacteria (GNB).[@b1-idr-11-1261] Nevertheless, these agents have been misused to the extent that they are no longer effective due to the high rate of development of different resistant mechanisms that target them.[@b2-idr-11-1261]

Among these resistant mechanisms, acquired carbapenem hydrolyzing enzymes (carbapenemases) emergence and their wide dissemination represented a global health threat which poses serious therapeutic and infection control challenges being associated with elevated mortality rates and increase in hospital stay.[@b3-idr-11-1261],[@b4-idr-11-1261] For these reasons, clinicians became highly concerned about rapidly identifying bacteria carrying these genes to reduce or prevent this problem in health care centers.[@b5-idr-11-1261]

Carbapenemases are diverse and include members of β-lactamase molecular classes A, B and D.[@b6-idr-11-1261] Class D oxacillinases (OXA type) are the most prevalent in *Acinetobacter baumannii* while in *Pseudomonas aeruginosa*, carbapenemases are mostly class B (metallo-β-lactamases).[@b7-idr-11-1261],[@b8-idr-11-1261]

Although the definitions for MDR and XDR (multi- and extensively drug-resistant) GNB do not necessarily require resistance to carbapenems,[@b9-idr-11-1261] the carbapenem-resistant (CR) phenotype is very common for MDR and particularly for XDR isolates because carbapenemase-encoding genes are carried on mobile genetic elements that usually carry genetic determinants for resistance to other antibiotics.[@b10-idr-11-1261]

The lack of effective antibiotics against CR-GNB and the drying out of the pipeline of new antibiotics forced physicians to recall old antibiotics (ie, polymyxins) back into clinical use.[@b11-idr-11-1261] Most CR-GNB, including those with XDR profile, show in vitro susceptibility to colistin.[@b12-idr-11-1261] However, the possibility of emergence of hetero-resistance and the low clinical efficacy of colistin in monotherapy in addition to its high toxicity, led to the utilization of colistin in combination with other antibiotics for desperately ill patients with serious infections especially in intensive care units (ICUs).[@b13-idr-11-1261]

The E-test method for antibiotic combination testing is an easily performed, rapid method that showed good concordance with other methods used for evaluating the effect of antibiotic combinations.[@b14-idr-11-1261],[@b15-idr-11-1261] It is thus reliable when results are to be used in guiding combination therapies.[@b16-idr-11-1261]

This study was conducted to characterize different carbapenemase genes carried by CR *A. baumannii* and *P. aeruginosa* isolates and to evaluate the in vitro effect of some colistin-based combinations by E-test method in Zagazig University Hospitals ICU isolates.

Materials and methods
=====================

Bacterial isolates and primary susceptibility testing
-----------------------------------------------------

Fifty *A. baumannii* and 43 *P. aeruginosa* non-duplicate clinical isolates collected over a 6-month period (July 2017--December 2017) from the surgical ICU of Zagazig University Hospitals were included in the study. Identification was done by Vitek 2 system (Biomerieux, Marcy l'Etoile, France). The designation *"A. baumannii*" here is used to refer to the pathogenic members of the *Acinetobacter baumannii complex*.

Isolates were tested for antimicrobial susceptibility by the modified Kirby-Bauer disc diffusion method. Antimicrobial susceptibility included that of carbapenems (imipenem and meropenem), aminoglycosides (amikacin and tobramycin), antipseudomonal penicillin/β-lactamase inhibitor (piperacillin/tazobactam), monobactam (aztreonam), broad spectrum cepha-losporins (ceftazidime, cefepime), and antipseudomonal fluoro-quinolones (ciprofloxacin, levofloxacin). Minimum inhibitory concentration (MIC) values of meropenem and colistin were detected by broth microdilution method in those isolates found resistant to carbapenems and sub-cultures of these isolates on glycerol broth were stored at −20°C. *P. aeruginosa* ATCC^®^27853 was used as a quality control strain (American Type Culture Collection \[ATCC\], Manassas, VA, USA).

Detection of *bla* genes responsible for carbapenem resistance in CR isolates by polymerase chain reaction (PCR)
----------------------------------------------------------------------------------------------------------------

Bacterial DNA was extracted from isolated colonies using QIAamp^®^ DNA Mini kit (Qiagen GmbH, Hilden, Germany). Amplification was done using Taq PCR Master Mix (Qiagen GmbH). Two multiplex PCRs were done; the first was for detection of genes encoding class A carbapenemase (*bla*~KPC~ and *bla*~GES~) and genes encoding class B metallo-beta-lactamases (MBL) (*bla*~IMP~ and *bla*~VIM~) in all isolates using primers and conditions described by Monteiro et al.[@b5-idr-11-1261] *Klebsiella pneumoniae* ATCC BAA-1705 was used as the positive control for *bla*~KPC~. The other multiplex PCR was for detection of genes encoding class D carbapenemase (OXA-type carbapenemase) (*bla*~OXA-23~, *bla*~OXA-24~, *bla*~OXA-58~, *bla*~OXA-143~) in *A. baumannii* isolates only as described by Woodford et al and Higgins et al.[@b17-idr-11-1261],[@b18-idr-11-1261] Detection of (*bla*~NDM~) genes encoding New Delhi metallo-beta-lactamases (NDM) was performed in a separate reaction for all isolates as described by Poirel et al.[@b19-idr-11-1261]

Individual MIC values determination by E-test
---------------------------------------------

MIC values of meropenem and colistin against all isolates and MIC values of tigecycline against *A. baumannii* isolates were determined separately by E-test to be used in fractional inhibitory concentration (FIC) calculation. *P. aeruginosa* ATCC^®^27853 was used as a quality control strain. Results were interpreted according to the Clinical and Laboratory Standards Institute 2017,[@b20-idr-11-1261] except for the MIC values of tige-cycline against *A. baumannii* where the standards specified for the *Enterobacteriaceae* family by the US Food and Drug Administration were used (susceptible, MIC ≤2 µg/mL, intermediate, MIC is \>2 to \<8 µg/mL, resistant, MIC ≥8 µg/mL).[@b21-idr-11-1261]

Antimicrobial combination testing
---------------------------------

The effect of antimicrobial combinations was evaluated for colistin/meropenem and colistin/tigecycline in *A. baumannii* isolates and for colistin/meropenem in *P. aeruginosa* isolates by "Perpendicular E-test" method. Briefly, E-test strips of the two antimicrobials were placed on the agar at right angles intersecting at the respective MIC values previously determined for each antibiotic separately against the isolate. The agar plates were then incubated at 37°C for 18 hours. The MIC value of each antimicrobial in the combination was read.[@b22-idr-11-1261]

The fractional inhibitory concentration index (∑ FIC) was calculated for each antimicrobial combination according to the following formula: ∑ FIC = FIC \[A\]+ FIC \[B\][@b23-idr-11-1261]

FIC \[A\]= MIC drug A when tested in combination with drug B/MIC of drug A alone

FIC \[B\]= MIC drug B when tested in combination with drug A/MIC of drug B alone

Interpretation of the ∑ FIC results was done as follows: ≤0.5, synergy; \>0.5 to ≤1.0, additively; \>1.0 to \<4.0, indifference; and ≥4, antagonism.[@b23-idr-11-1261]

When the individual MIC value of an isolate was more than the highest concentration on any of the E-test strips, the strips were placed intersecting at the highest concentration present on this E-test strip. The MIC value used to calculate the FIC index was then considered as one 2-fold dilution above the highest concentration on the E-test strip.[@b14-idr-11-1261] This was necessary for meropenem in most of the isolates where individual MIC values for meropenem were ≥32 µg/mL.

This study was approved by the institutional review board (IRB) -- Faculty of Medicine, Zagazig University. A written informed consent was obtained from each patient or the guardians of unconscious patients.

Results
=======

Thirty out of 50 *A. baumannii* isolates (60%) and 22 out of 43 *P. aeruginosa* isolates (51%) tested were CR; they showed resistance to imipenem and meropenem by disc diffusion method as well as resistance to meropenem by broth microdi-lution (ie, MIC ≥8 µg/mL). These isolates were also resistant to the majority of the tested antibiotic classes expressing an MDR or XDR phenotype.

PCR results showed that all CR *A. baumannii* isolates harbored at least one of the genes under investigation. The most common resistance gene was *bla*~OXA-23~ in 90% of the isolates (27/30) followed by *bla*~NDM~ in 66.7% of the isolates (20/30), then *bla*~GES~ in 50% of the isolates (15/30), while the *bla*~KPC~, *bla*~IMP~, *bla*~VIM~, *bla*~OXA-24~, *bla*~OXA-58~ and *bla*~OXA-143~ genes were not detected. On the other hand, all CR *P. aeruginosa* isolates harbored at least one of the tested genes except a single isolate in which none of the tested genes was detected. They showed high prevalence of class B carbapenemases where 18/22 (81.8%) harbored at least one of the tested MBL genes. Meanwhile *bla*~GES~ was the only serine carbapenemase gene detected in (40.9%) of *P. aeruginosa* isolates ([Table 1](#t1-idr-11-1261){ref-type="table"}).

Meropenem MICs for *CR A. baumannii* isolates by broth dilution method ranged from 32 to 512 µg/mL ([Table 2](#t2-idr-11-1261){ref-type="table"}). By E-test, all meropenem MIC values were ≥32 µg/mL (ie, the maximum value on meropenem strip). All these isolates were colistin-sensitive by broth microdilution, where colistin MIC values ranged from 0.38 to 1.5 µg/mL. However, 15 isolates (50%) were tigecycline-resistant (MIC ≥8 µg/mL), 12 isolates (40%) were intermediate and three isolates (10%) were tigecycline-sensitive (MIC ≤2 µg/mL). MIC for tigecycline by E-test ranged from 2 to −16 µg/mL.

Meropenem MICs for CR *P. aeruginosa* isolates by broth dilution method ranged from 32 to 512 µg/mL ([Table 2](#t2-idr-11-1261){ref-type="table"}). By E-test, all meropenem MIC values were ≥32 µg/mL. MICs for colistin ranged from 0.38 to 16 µg/mL. Twenty isolates (90.9%) were colistin-sensitive (MIC ≤2 µg/mL), and two isolates (9.1%) were resistant (MIC ≥4 µg/mL).

In the 30 CR *A. baumannii* isolates tested, both colistin/meropenem and colistin/tigecycline combination showed additive effects against most of the isolates; 25 (83.3%) and 18 (60%), respectively ([Figure 1](#f1-idr-11-1261){ref-type="fig"}), but synergism was only detected for colistin/tigecycline combination in six isolates (20%). Meanwhile, no antagonism was detected for either combinations ([Table 3](#t3-idr-11-1261){ref-type="table"}).

Out of 22 CR *P. aeruginosa* isolates tested, the colistin/meropenem combination showed synergistic effects against most 14 (63.6%) isolates ([Figure 2](#f2-idr-11-1261){ref-type="fig"}) and additive effect in eight (36.4%) isolates ([Table 3](#t3-idr-11-1261){ref-type="table"}).

Discussion
==========

This study depicts the increasingly reported threat of carbape-nem resistance in the two frequently isolated Gram negative non-fermentative bacilli in Zagazig University Hospitals (ie, *A. baumannii* and *P. aeruginosa*), where 60% of *A. bauman-nii* and 43% of *P. aeruginosa* isolated over a 6-month period were CR. They all showed high level meropenem resistance with MIC values ranging from 32 to 512 µg/mL. In addition, they all exhibited an MDR profile being non-susceptible to at least one agent in at least three of the tested antimicrobial classes. This is attributed to the fact that mobile genetic elements carrying carbapenemase genes also carry genetic determinants of other antimicrobial resistance.

Screening our CR isolates for nine carbapenemase genes previously reported in our region yielded at least a single PCR product in 51/52 isolates which underscores the production of carbapenem-hydrolyzing enzymes as a common mechanism for high level carbapenem resistance displayed by our isolates. In a study in Saudi Arabia only 11 of 39 (18%) CR *P. aeruginosa* yielded a PCR product for carbapen-emase genes.[@b24-idr-11-1261] Extended spectrum β-lactamases (ESBLs), porin mutations and/or presence of efflux pumps are other carbapenem resistance mechanisms that were implicated in carbapenem resistance in the absence of carbapenemase genes in tested isolates.[@b25-idr-11-1261]

In CR *A. baumannii* isolates, *bla*OXA-23 was the most frequent carbapenemase gene and the only OXA-type car-bapenemase detected in 27/30 (90%), followed by *bla*~NDM~ in 20/30 (66.7%) then *bla*~GES~ in 15/30 (50%). Kateete et al, in another African study, reported *bla*~OXA-23~ 60% (9/15) as the most frequent OXA-type carbapenemase gene detected in CR *A. baumannii* followed by *bla*~OXA-58~ (2/15, 13%) and *bla*~OXA-24~ (1/15, 7%), while *bla*~VIM~ was the only metallo-β-lactamase detected in 2/15 (13%) in such isolates.[@b26-idr-11-1261] The *bla*~KPC~ gene, the metallo-β-lactamases (VIM, IMP) genes as well as other tested OXA-type genes were not detected in our CR *A. baumannii* isolates.

*A. baumannii* strains harboring *blaOXA-23* have been reported to emerge around the world replacing *bla*~OXA-58~ that predominated for a long period among CR *A. baumannii* isolates and became the most prevalent carbapenemase gene circulating in different Mediterranean countries including Egypt.[@b27-idr-11-1261],[@b28-idr-11-1261] The higher carbapenemase activity of OXA-23 and/or horizontal gene transfer might provide a selective advantage for such isolates.[@b29-idr-11-1261]

KPCs and GES-type class A carbapenemases have been described in *A. baumannii*.[@b30-idr-11-1261] Only GES-type carbapenemase was reported in Mediterranean countries. In addition, a Turkish study found that *A. baumannii* strains that belong to ST2, a part of the worldwide distributed clone II group, co-harbor both *bla*~OXA-23~ and *bla*~GES-11~.[@b31-idr-11-1261] This applies to the current study where *bla*~GES~, and not *bla*~KPC~, was detected and coexisted with *bla*~OXA-23~ in 12/30 (40%) of CR *A. baumannii* isolates.

In Egypt NDM-1 and NDM-2 encoding genes have been reported since 2011.[@b32-idr-11-1261],[@b33-idr-11-1261] Another Egyptian study identified MBL-encoding genes *bla*~VIM~ and *bla*~NDM-1~ in 86.4% and 59.1% of MBL-producing *A. baumannii* isolates, respectively.[@b34-idr-11-1261]

In CR *P. aeruginosa* isolates, *bla*~GES~ was detected in 40.9% of the isolates (9/22). Metallo-β-lactamase (MBL) genes were detected in 18/22 isolates including *bla*~IMP~ (18.2%, 4/22), *bla*~VIM~ (50%, 11/22), and *bla*~NDM~ (27.3%, 6/22). In a study in Saudi Arabia, two MBL types, VIM and/or IMP, were detected in 12/34 CR *P. aeruginosa* isolates.[@b24-idr-11-1261] In Uganda, metallo-β-lactamase genes detected in CR *P. aeruginosa* were *bla*~IMP1~ (36%, 9/25), *bla*~IMP2~ (4%, 1/25), *bla*~VIM1~ (32%, 8/25), and *bla*~NDM1~ (4%, 1/25).[@b26-idr-11-1261]

The KPC enzyme-encoding gene (*bla*~KPC~), known to be prevalent among *Enterobacteriaceae*, was not detected in our isolates but was identified in *Pseudomonas* (16.9%) and *Acinetobacter spp*. (11.9%) from another Egyptian study.[@b35-idr-11-1261]

In the past few years, antibiotic combination therapy has been employed as the standard for treating severe infections by CR GNB, particularly those with an XDR profile, justified by the possible additive or synergistic effect of adding drugs and by the broad spectrum activity that suppresses the emergence of resistant subpopulations if one antibiotic is used.[@b36-idr-11-1261] However, the irrational use of antibiotic combinations can worsen the existing antibiotic resistance problem. Thus, antibiotic combination should be rationally optimized based on preliminary in-vitro or animal studies followed by clinical trials on human subjects. Experts further recommend that combinations should be individualized based on the agent involved, its antibiotic susceptibility pattern, the type of infection and the patient's characteristics.[@b13-idr-11-1261]

So far, most CR GNB are susceptible to colistin. In the present study all CR *A. baumannii* and 90.9% of CR *P. aeru-ginosa* isolates were colistin-sensitive and this nominates colistin to be a cornerstone drug in combination therapy. In CR *A. baumannii*, the colistin/meropenem combination showed additive effects in most (83.3%) of the isolates and indifferent effects in only 16.7%. This agrees with a recent Lebanese study where 'Perpendicular E-tests' showed additive effects of the colistin/meropenem combination in *A. baumannii*. Synergy, however, was not detected in either studies but a reduction of colistin MIC in combination means lower doses of colistin can be used in therapy, thus minimizing its toxic effects.[@b16-idr-11-1261] In CR *P. aeruginosa*, the colistin/meropenem combination showed better results where synergistic and additive effects were detected in 63.6% and 36.4% of the isolates, respectively. Daoud et al on testing this combination, found that six strains (54.5%) of *A. baumannii* and three (27.3%) strains of *P. aeruginosa* showed synergy while five (45.5%) strains of *A. baumannii* and seven (63.3%) strains of *P. aeruginosa* showed additive effect, while only one (9%) strain of *P. aeruginosa* showed antagonism.[@b37-idr-11-1261]

On the other hand, the colistin/tigecycline combination against CR *A. baumannii* isolates showed synergistic, additive and indifferent effects in six (20%), 18 (60%) and six (20%), respectively. Karaoglan et al found that 96% and 64% of CR *A. baumannii* isolates were colistin- and tigecycline-sensitive, respectively. Meanwhile, the colistin/tigecycline combination revealed synergistic effects in 12% of such isolates.[@b38-idr-11-1261] Ni et al in a study on MDR *A. baumannii* strains, reported that the colistin/tigecycline combination had a synergistic effect in 24.3%.[@b39-idr-11-1261] In contrast, a recent Turkish study found colistin/tigecycline combination synergistic in 2%, additive in 6%, indifferent in 88%, and antagonistic in 4% of *A. baumannii* isolates; all were tigecycline- and colistin-sensitive, concluding that the colistin/tigecycline combination is not an optimal treatment choice.[@b40-idr-11-1261]

The synergistic or additive outcome of the colistin-based combination could be due to its ability to disrupt the bacterial outer membrane which facilitates the entry of the other agents into the bacterial cell. In addition, discrepant results of antibiotic combinations in different studies could be due to the different antibiotic selective pressure and genetic makeup of the isolates leading to their differential adaptation in different environments and consequently difference in their response to antimicrobial agents.[@b16-idr-11-1261]

Conclusion
==========

High level carbapenem resistance detected in CR *A. bauman-nii* and CR *P. aeruginosa* in this study is attributed to the carriage of carbapenemase genes in different combinations. Colistin/tigecycline and colistin/meropenem combinations can be considered for treatment of severe infections by CR *A. baumannii* and *P. aeruginosa*, respectively, after adequate review of relevant pharmacodynamic and pharmacokinetic data. Moreover, the in vivo efficacy of these combinations needs to be proved by further clinical studies.

Limitations of the study
========================

Primers used in this study amplify all alleles of the GES gene. So, a sequencing step would be helpful to differentiate between alleles of GES gene with ESBL and carbapenemase activities.

Supplementary materials
=======================

###### 

Individual MIC values of tested agents, FIC values of tested combinations and corresponding carbapenemase gene/s for all *Acinetobacter baumannii* isolates

       MIC (μg/mL)   Colistin + tigecycline   Colistin + meropenem   *bla* gene/s                                                                  
  ---- ------------- ------------------------ ---------------------- -------------- ------ ------- ------------- ------- ---- ------ ------------- -------------
  1    256           0.5                      12                     0.125          3      0.5     synergy       0.25    32   1      additive      OXA-GES-NDM
  2    128           1.5                      6                      0.75           3      1       additive      0.75    32   1      additive      OXA-GES
  3    256           0.38                     16                     0.125          8      0.83    additive      0.125   32   0.83   additive      OXA-NDM
  4    128           1                        16                     0.5            8      1       additive      0.38    32   0.88   additive      OXA-GES
  5    128           0.5                      8                      0.125          3      0.625   additive      0.25    32   1      additive      OXA-NDM
  6    64            0.75                     6                      0.5            1      0.83    additive      0.25    32   0.83   additive      OXA-NDM
  7    64            1.5                      2                      0.5            1      0.83    additive      1.0     32   1.17   indifferent   OXA-NDM
  8    512           0.75                     3                      0.25           1      0.66    additive      0.25    32   0.83   additive      OXA-GES
  9    32            0.5                      3                      0.125          1.5    0.75    additive      0.25    16   1      additive      OXA-NDM
  10   64            0.75                     16                     0.25           2      0.46    synergy       0.25    32   0.83   additive      OXA-GES
  11   128           0.75                     8                      0.38           2      0.75    additive      0.25    32   0.83   additive      OXA-NDM
  12   512           0.75                     16                     0.25           3      0.52    additive      0.25    32   0.83   additive      OXA-NDM
  13   128           1                        3                      0.25           2      0.92    additive      0.50    32   1      additive      OXA-GES
  14   512           1                        16                     0.25           3      0.43    synergy       0.25    32   0.75   additive      OXA-NDM
  15   128           1                        3                      0.38           1      0.71    additive      0.38    32   0.88   additive      OXA-NDM
  16   256           0.38                     6                      0.19           3      1       additive      0.125   32   0.83   additive      GES-NDM
  17   32            1.5                      8                      1              4      1.16    indifferent   0.75    12   0.87   additive      GES
  18   512           0.5                      6                      0.19           3      0.88    additive      0.25    32   1      additive      OXA-NDM
  19   128           0.5                      8                      0.38           4      1.26    indifferent   0.25    32   1      additive      OXA-GES
  20   128           0.75                     6                      0.38           4      1.17    indifferent   0.25    32   0.83   additive      OXA-NDM
  21   128           1                        6                      0.38           4      1.05    indifferent   0.38    32   0.88   additive      OXA-GES
  22   128           0.75                     8                      0.5            2      0.92    additive      0.50    32   1.17   indifferent   OXA-GES-NDM
  23   256           0.75                     6                      0.25           1      0.49    synergy       0.25    32   0.83   additive      GES-NDM
  24   128           0.75                     2                      0.25           0.75   0.71    additive      0.25    32   0.83   additive      OXA-NDM
  25   64            0.75                     16                     0.5            1      0.73    additive      0.50    32   1.17   indifferent   OXA-GES
  26   512           0.75                     16                     0.5            6      1.04    indifferent   0.38    32   1.01   indifferent   OXA-NDM
  27   256           0.75                     6                      0.25           1      0.49    synergy       0.38    32   1.01   indifferent   OXA-GES-NDM
  28   64            1                        12                     0.25           3      0.5     synergy       0.25    32   0.75   additive      OXA-GES
  29   256           0.38                     8                      0.19           3      0.875   additive      0.125   32   0.83   additive      OXA-NDM
  30   64            1.5                      2                      1              1      1.16    indifferent   0.75    32   1      additive      OXA-NDM

**Abbreviations:** FIC, fractional inhibitory concentration; MIC, minimum inhibitory concentration; CL, colistin; MEM, meropenem; TGC, tigecycline.

###### 

Individual MIC values of tested agents, FIC values of tested combination and corresponding carbapenemase gene/s for all *Pseudomonas aeruginosa* isolates

       MIC (µg/mL)   Colistin + meropenem combination   *bla* gene/s                          
  ---- ------------- ---------------------------------- -------------- ---- ------ ---------- ---------
  1    128           0.75                               0.25           2    0.36   synergy    GES-VIM
  2    256           16                                 3              8    0.31   synergy    GES-VIM
  3    128           1                                  0.38           2    0.41   synergy    VIM-IMP
  4    128           1                                  0.5            4    0.56   additive   NDM
  5    64            2                                  1              1    0.51   additive   GES-IMP
  6    128           1.5                                0.38           2    0.28   synergy    NDM
  7    256           1                                  0.25           8    0.38   synergy    VIM
  8    128           0.75                               0.5            4    0.73   additive   IMP-NDM
  9    128           0.75                               0.25           2    0.36   synergy    GES-IMP
  10   512           2                                  1              16   0.75   additive   VIM
  11   32            2                                  0.38           1    0.22   synergy    NDM
  12   256           1.5                                0.75           16   0.75   additive   GES-VIM
  13   128           2                                  1              4    0.56   additive   NDM
  14   512           0.75                               0.25           16   0.58   additive   GES
  15   128           0.5                                0.125          2    0.28   synergy    VIM-NDM
  16   64            0.38                               0.125          1    0.34   synergy    GES
  17   256           1                                  0.25           8    0.38   synergy    VIM
  18   64            1.5                                0.50           2    0.36   synergy    VIM
  19   256           8                                  2              8    0.38   synergy    GES-VIM
  20   128           2                                  1.5            4    0.81   additive   VIM
  21   32            0.75                               0.25           1    0.36   synergy    \-
  22   128           0.5                                0.125          2    0.28   synergy    GES

**Notes:** Meropenem MIC values \>32 µg/mL (highest concentration on E-test strip) were calculated as 64 µg/mL (two-fold dilution above highest concentration on E-test strip).

**Abbreviations:** FIC, fractional inhibitory concentration; MIC, minimum inhibitory concentration.
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![Colistin/tigecycline combination test (*Acinetobacter baumannii*).\
**Notes:** The MIC of colistin was 0.75 µg/mL when tested alone but was 0.25 µg/mL when tested in combination. The MIC of tigecycline was 16 µg/mL when tested alone but was 3 µg/mL when tested in combination. This was an additive effect (isolate no. 12; [Table S1](#SD1-idr-11-1261){ref-type="supplementary-material"}).\
**Abbreviation:** MIC, minimum inhibitory concentration.](idr-11-1261Fig1){#f1-idr-11-1261}

![Colistin/meropenem combination test *(Pseudomonas aeruginosa)*.\
**Notes:** The MIC of colistin was 0.75 µg/mL when tested alone but was 0.25 µg/mL when tested in combination. The MIC of meropenem was \>32 µg/mL when tested alone but was 2 µg/mL when tested in combination. This was a synergistic effect (isolate no. 1; [Table S2](#SD2-idr-11-1261){ref-type="supplementary-material"}).\
**Abbreviation:** MIC, minimum inhibitory concentration.](idr-11-1261Fig2){#f2-idr-11-1261}

###### 

*bla* genes detected by PCR in carbapenem resistant isolates

  *bla* genes          Class A      Class B      Class D               Total + *ve*                                                           
  -------------------- ------------ ------------ --------------------- -------------- --------- ----------- --------- ------- ------- ------- -----------
  ***A baumannii***    **No (%)**   0 (0)        15 (50)               0 (0)          0 (0)     20 (66.7)   27 (90)   0 (0)   0 (0)   0 (0)   30 (100)
                       **Total**    15 (50%)     20 (66.7%)            27 (90%)                                                               
  ***P aeruginosa***   **No (%)**   0 (0)        9 (40.9)              4 (18.2)       11 (50)   6 (27.3)    NA        NA      NA      NA      21 (95.5)
  **Total**            9 (40.9%)    18 (81.8%)   NA (not applicable)                                                                          

**Abbreviations:** A baumannii, Acinetobacter baumannii; P aeruginosa, Pseudomonas aeruginosa; PCR, polymerase chain reaction.

###### 

Carbapenemase gene distribution among isolates, the corresponding meropenem MIC range and the effect of antimicrobial combination

  No. of isolates             Carbapenemase genes detected   Meropenem MIC range[a](#tfn2-idr-11-1261){ref-type="table-fn"}   FIC (range)/effect of combination   
  --------------------------- ------------------------------ ---------------------------------------------------------------- ----------------------------------- -----------------------------
  *Acinetobacter baumannii*                                                                                                                                       
   15                         OXA-23 + NDM                   32--512                                                          (0.75--1.17) add/indiff             (0.43--1.17) syn/add/indiff
   9                          OXA-23 + GES                   64--512                                                          (0.75--1.17) add/indiff             (0.46--1.26) syn/add/indiff
   2                          NDM + GES                      256                                                              (0.83) additive                     (0.49--1) syn/add
   3                          OXA-23 + GES + NDM             128--256                                                         (1--1.17) add/indiff                (0.49--0.92) syn/add
   1                          GES only                       32                                                               (0.87) add                          (1.16) indiff
  *Pseudomonas aeruginosa*                                                                                                                                        
   5                          VIM only                       64--512                                                          (0.36--0.81) syn/add                NA (not applicable)
   3                          GES only                       64--512                                                          (0.28--0.58) syn/add                NA
   4                          NDM only                       32--128                                                          (0.22--0.56) syn/add                NA
   4                          VIM + GES                      128--256                                                         (0.31--0.75) syn/add                NA
   2                          IMP + GES                      64--128                                                          (0.36--0.51) syn/add                NA
   1                          NDM + IMP                      128                                                              (0.73) add                          NA
   1                          NDM + VIM                      128                                                              (0.28) syn                          NA
   1                          VIM + IMP                      128                                                              (0.41) syn                          NA
   1                          None detected                  32                                                               (0.36) syn                          NA

**Notes:**

Measured by broth microdilution method.

**Abbreviations:** FIC, fractional inhibitory concentration; MIC, minimum inhibitory concentration; add, additive; indiff, indifference; syn, synergy.

###### 

The effect of colistin based combinations against *Acinetobacter baumannii* and *Pseudomonas aeruginosa*

  Antimicrobial combination   Synergy No (%)   Additive No (%)   Indifferent No (%)   Antagonism No (%)   Mean FIC (SD)   Min/Max FIC
  --------------------------- ---------------- ----------------- -------------------- ------------------- --------------- -------------
  COL/MEM                                                                                                                 
  *A. baumannii*              0/30 0%          25/30 (83.3%)     5/30 (16.7%)         0/30 0%             0.95 (0.18)     0.75/1.17
  *P. aeruginosa*             14/22 (63.6%)    8/22 (36.4%)      0/22 0%              0/22 0%             0.49 (0.26)     0.22/0.81
  COL/TGC                                                                                                                 
  *A. baumannii*              6/30 (20%)       18/30 (60%)       6/30 (20%)           0/30 (0%)           0.8 (0.24)      0.43/1.26

**Abbreviations:** COL, colistin; MEM, meropenem; TGC, tigecycline.
